SCHEMBL3322113

SCHEMBL3322113

CCOC(=O)c1cc2c(-c3ccccc3)nc(N)nc2s1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AB1 P08238 4/20 0.69
ALDH1A1 P00352 5/20 0.55
HSD17B10 Q99714 3/20 0.55
KDM4E B2RXH2 4/20 0.52
HPGD P15428 4/20 0.52
RAB9A P51151 3/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
NPC1 O15118 2/20 0.52
CDC7 O00311 3/20 0.48
DBF4 Q9UBU7 3/20 0.48
MAPT P10636 3/20 0.47
GAA P10253 2/20 0.47
MAPK1 P28482 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
ALOX15 P16050 1/20 0.47
RARA P10276 1/20 0.46
RARB P10826 1/20 0.46
RARG P13631 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13109525 0.91 HSP90AB1 (0.57) HSP90AB1ALDH1A1HSD17B10KDM4EHPGD
SCHEMBL13109512 0.90 HSP90AB1 (0.56) HSP90AB1ALDH1A1HSD17B10KDM4EHPGD
SCHEMBL3950227 0.90 HSP90AB1 (0.55) HSP90AB1ALDH1A1HSD17B10KDM4EHPGD
SCHEMBL17355415 0.90 HSP90AB1 (0.56) HSP90AB1ALDH1A1HSD17B10KDM4EHPGD
SCHEMBL13109969 0.89 HSP90AB1 (0.70) HSP90AB1ALDH1A1HSD17B10MAPTKMT2A
SCHEMBL13109522 0.89 HSP90AB1 (0.55) HSP90AB1ALDH1A1HSD17B10KDM4EHPGD
SCHEMBL13109747 0.88 KDM4E (0.57) HSP90AB1ALDH1A1HSD17B10KDM4EHPGD
SCHEMBL13109530 0.88 HSP90AB1 (0.55) HSP90AB1ALDH1A1HSD17B10KDM4EHPGD
SCHEMBL13109596 0.88 HSP90AB1 (0.54) HSP90AB1ALDH1A1HSD17B10KDM4EHPGD
SCHEMBL13109527 0.88 HSP90AB1 (0.54) HSP90AB1ALDH1A1HSD17B10KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1675861-B1 PYRIMIDOTHIOPHENE COMPOUNDS VERNALIS R&D LTD (GB) 2015-12-23 EP disclosed
EP-1675861-B1 PYRIMIDOTHIOPHENE COMPOUNDS VERNALIS R&D LTD (GB) 2015-12-23 EP disclosed
US-8642594-B2 Substituted thieno[2,3-d]pyrimidines as HSP90 inhibitors VERNALIS (R&D) LIMITED (GB) 2014-02-04 US disclosed
US-8642594-B2 Substituted thieno[2,3-d]pyrimidines as HSP90 inhibitors VERNALIS (R&D) LIMITED (GB) 2014-02-04 US disclosed
US-8642594-B2 Substituted thieno[2,3-d]pyrimidines as HSP90 inhibitors VERNALIS (R&D) LIMITED (GB) 2014-02-04 US disclosed
US-7820658-B2 Substituted thieno[2,3-d]pyrimidines as HSP90 inhibitors VERNALIS (CAMBRIDGE) LIMITED (GB) 2010-10-26 US disclosed
US-7820658-B2 Substituted thieno[2,3-d]pyrimidines as HSP90 inhibitors VERNALIS (CAMBRIDGE) LIMITED (GB) 2010-10-26 US disclosed
US-7820658-B2 Substituted thieno[2,3-d]pyrimidines as HSP90 inhibitors VERNALIS (CAMBRIDGE) LIMITED (GB) 2010-10-26 US disclosed
US-20100120767-A1 Pyrimidothiophene Compounds Barril-Alonso, Xavier (GB) 2010-05-13 US disclosed
US-20100120767-A1 Pyrimidothiophene Compounds Barril-Alonso, Xavier (GB) 2010-05-13 US disclosed
US-20100120767-A1 Pyrimidothiophene Compounds Barril-Alonso, Xavier (GB) 2010-05-13 US disclosed
US-20070043044-A1 Pyrimidothiophene compounds VERNALIS (CAMBRIDGE) LIMITED (GB) 2007-02-22 US disclosed
US-20070043044-A1 Pyrimidothiophene compounds VERNALIS (CAMBRIDGE) LIMITED (GB) 2007-02-22 US disclosed
US-20070043044-A1 Pyrimidothiophene compounds VERNALIS (CAMBRIDGE) LIMITED (GB) 2007-02-22 US disclosed
EP-1675861-A1 PYRIMIDOTHIOPHENE COMPOUNDS Vernalis (Cambridge) Limited (GB) 2006-07-05 EP disclosed
WO-2005021552-A1 PYRIMIDOTHIOPHENE COMPOUNDS VERNALIS (CAMBRIDGE) LTD (GB) 2005-03-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100120767-A1 Pyrimidothiophene Compounds ALK, HSP90AA1, HSP90AB1 HSP90AB1 3/4885ALDH1A1 83/4885HSD17B10 566/4885
US-20070043044-A1 Pyrimidothiophene compounds ALK, HSP90AA1, HSP90AB1 HSP90AB1 3/4885ALDH1A1 91/4885HSD17B10 635/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.